{"Title": "The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia", "Year": 2020, "Source": "Br. J. Haematol.", "Volume": "188", "Issue": 6, "Art.No": null, "PageStart": 918, "PageEnd": 923, "CitedBy": 1, "DOI": "10.1111/bjh.16271", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85074798540&origin=inward", "Abstract": "\u00a9 2019 British Society for Haematology and John Wiley & Sons LtdElderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Bruton's tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories \u226575 and <75 years treated in the relapsed, refractory non-trial setting. We demonstrate that venetoclax has equivalent efficacy and safety in relapsed/refractory CLL patients who are elderly, the majority of whom are previous ibrutinib-exposed and therefore may otherwise have few clear therapeutic options.", "AuthorKeywords": ["BCL2", "chronic lymphocytic leukaemia", "elderly", "venetoclax"], "IndexKeywords": ["Aged", "Antineoplastic Agents", "Bridged Bicyclo Compounds, Heterocyclic", "Humans", "Leukemia, Lymphocytic, Chronic, B-Cell", "Recurrence", "Sulfonamides"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85074798540", "SubjectAreas": [["Hematology", "MEDI", "2720"]], "AuthorData": {"55496044000": {"Name": "Eyre T.A.", "AuthorID": "55496044000", "AffiliationID": "60170323", "AffiliationName": "Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust"}, "54388293300": {"Name": "Roeker L.E.", "AuthorID": "54388293300", "AffiliationID": "60009343", "AffiliationName": "Leukemia Service, Memorial Sloan-Kettering Cancer Center"}, "13609163500": {"Name": "Mato A.R.", "AuthorID": "13609163500", "AffiliationID": "60009343", "AffiliationName": "Leukemia Service, Memorial Sloan-Kettering Cancer Center"}, "57202632412": {"Name": "Fox C.P.", "AuthorID": "57202632412", "AffiliationID": "60025016", "AffiliationName": "Department of Clinical Haematology, Nottingham University Hospitals NHS Foundation Trust"}, "57206185357": {"Name": "Gohill S.H.", "AuthorID": "57206185357", "AffiliationID": "60024544", "AffiliationName": "Department of Haematology, University College London Hospitals"}, "6508152534": {"Name": "Walewska R.", "AuthorID": "6508152534", "AffiliationID": "60032889", "AffiliationName": "Department of Haematology, Royal Bournemouth Hospital"}, "57117207300": {"Name": "Walter H.S.", "AuthorID": "57117207300", "AffiliationID": "60007974", "AffiliationName": "Department of Oncology, Leicester Royal Infirmary"}, "6602116911": {"Name": "Forconi F.", "AuthorID": "6602116911", "AffiliationID": "60025287, 60172638", "AffiliationName": "National Institute for Health Research Experimental Cancer Medicine Centres, Faculty of Medicine, University of Southampton"}, "57204932130": {"Name": "Broom A.", "AuthorID": "57204932130", "AffiliationID": "60013999", "AffiliationName": "Department of Haematology, Western General Hospital"}, "16835979800": {"Name": "Arumainathan A.", "AuthorID": "16835979800", "AffiliationID": "60020939", "AffiliationName": "Clatterbridge Cancer Centre NHS Foundation Trust"}, "23026920500": {"Name": "Brander D.M.", "AuthorID": "23026920500", "AffiliationID": "60018749, 60004654", "AffiliationName": "Duke Cancer Institute, Duke University Health System"}, "57193122968": {"Name": "Allan J.N.", "AuthorID": "57193122968", "AffiliationID": "60007997", "AffiliationName": "Division of Hematology and Oncology, Weill Cornell Medicine"}, "7202029256": {"Name": "Schuster S.J.", "AuthorID": "7202029256", "AffiliationID": "60023009, 60006297", "AffiliationName": "Lymphoma Program, Abramson Cancer Center, University of Pennsylvania"}, "35603490100": {"Name": "Hill B.T.", "AuthorID": "35603490100", "AffiliationID": "60032732, 60021160", "AffiliationName": "Department of Hematology & Medical Oncology, Taussig Cancer Institute, Cleveland Clinic Foundation"}, "57200145871": {"Name": "Lansigan F.", "AuthorID": "57200145871", "AffiliationID": "60001844", "AffiliationName": "Dartmouth-Hitchcock Medical Center"}, "20133609200": {"Name": "Cheson B.D.", "AuthorID": "20133609200", "AffiliationID": "60020908, 60022986", "AffiliationName": "Georgetown University Hospital Lombardi Comprehensive Cancer Center"}, "8255874800": {"Name": "Lamanna N.", "AuthorID": "8255874800", "AffiliationID": "60027565", "AffiliationName": "Hematology/Oncology Division, Columbia University Medical Center"}, "56988994800": {"Name": "Coombs C.C.", "AuthorID": "56988994800", "AffiliationID": "60025111", "AffiliationName": "Lineberger Comprehensive Cancer Center, University of North Carolina"}, "22633898500": {"Name": "Barr P.M.", "AuthorID": "22633898500", "AffiliationID": "60024746, 60027165", "AffiliationName": "Wilmot Cancer Institute, University of Rochester"}, "8309266900": {"Name": "Skarbnik A.P.", "AuthorID": "8309266900", "AffiliationID": "101845763", "AffiliationName": "Novant Health"}, "13807841200": {"Name": "Shadman M.", "AuthorID": "13807841200", "AffiliationID": "60003625", "AffiliationName": "Fred Hutchinson Cancer Research Center"}, "35312637800": {"Name": "Ujjani C.S.", "AuthorID": "35312637800", "AffiliationID": "60003625", "AffiliationName": "Fred Hutchinson Cancer Research Center"}, "57209911983": {"Name": "Pearson L.", "AuthorID": "57209911983", "AffiliationID": "60001344", "AffiliationName": "Tufts Medical Center"}, "7006326906": {"Name": "Pagel J.M.", "AuthorID": "7006326906", "AffiliationID": "60011874", "AffiliationName": "Swedish Cancer Institute"}, "57118846100": {"Name": "Jacobs R.", "AuthorID": "57118846100", "AffiliationID": "60017501", "AffiliationName": "Levine Cancer Institute, Carolinas Healthcare System"}}}